{"prompt": "['73', 'MC1488 WEE1', 'MCCC', 'Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;', '53:457-481.', 'Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC,', 'Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lys\u00e1k D, Minden M,', 'Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice,', 'with physician advice, of either supportive care or low-dose cytarabine for the treatment of older', 'patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012 Jul 20;30(21):2670-7', 'Kimura H, Ng JM, Curran T (2008) Transient Inhibition of the Hedgehog Pathway in Young Mice', 'Causes Permanent Defects in Bone Structure. Cancer Cell;13:249-260.', 'Langerak P, Russell P. Regulatory networks integrating cell cycle control with DNA damage checkpoints', 'and double-strand break repair. Philos Trans R Soc Lond B Biol Sci. 2011 Dec', '27;366(1584):3562-71.', 'S. Leijen, J.H.M.S., G.I. Shapiro, A.C. Pavlick, R. Tibes, T. Demuth, J. Viscusi, J.D. Cheng, Y. Xu and', 'A.M. Oza. A Phase I Pharmacological and Pharmacodynamic Study of MK-1775, a Weel tyrosine', 'kinase inhibitor, in Both Monotherapy and in Combination with Gemcitabine, Cisplatin, or', 'Carboplatin in Patients With Advanced Solid Tumors. ASCO Annual Meeting (2010).', 'Long, B., Zhu, H., Zhu, C., Liu, T. & Meng, W. Activation of the Hedgehog pathway in chronic', 'myelogeneous leukemia patients. J Exp Clin Cancer Res 30, 8, (2011).', 'LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I,', 'Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD. Phase I trial of hedgehog', 'pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or', 'metastatic solid tumors. Clin Cancer Res. 2011 Apr 5;17(8):2502-11.', 'Maeda Y, Nakamura E, Nguyen MT, et al. (2007) Indian Hedgehog produced by postnatal chondrocytes', 'is essential for maintaining a growth plate and trabecular bone. The National Academy Sciences', 'of the USA; 104:6382-87.', 'Malone JO, Fedok FG, Belchis DA et al (2000) Basal Cell Carcinoma metastatic to the parotid: report of', 'a new case and review of the literature. Ear Nose Throat J; 79: 511-5, 518-9.', 'Marcil I, Stern R (2000) Risk of Developing a Subsequent Nonmelanoma Skin Cancer in Patients with', 'History of Nonmelanoma Skin Cancer. Arch Dermatol; 136:1524-30.', 'Mesa R. et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV', 'MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF', '(PMF-BP): Consensus on terminology by the international working group for', 'myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007 Jun;31(6):737-40.', 'Morita T. Plasma renin activity in acute respiratory acidosis. Jpn Circ J. 1976 Feb;40(2):123-6.', 'Mosterd K, Arits A, Thissen M et al (2009) Histology-based treatment of basal cell carcinoma. ACTA', 'Derm Venereol; 89:454-58', 'Mesa RA and Tibes R., MPN blast phase: Clinical challenge and assessing response. Leuk Res.']['74', 'MC1488 WEE1', 'MCCC', '2012 Sep 19.', 'Muzio L L (2008) Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet Journal of Rare', 'Diseases; 3:32-48.', 'Perry JA, Kornbluth S. Cdc25 and Weel : analogous opposites? Cell Div. 2007 May 4;2:12.', 'Pocock SJ, Simon R. Sequential Treatment Assignment with Balancing for Prognostic Factors', 'in the Controlled Clinical Trial. Biometrics :103-115, 1975 Mar.', 'Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel', 'PR, Gao D, Tan AC, DeGregori J. Integrated genomic analyses identify WEE1 as a', 'critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.', 'Leukemia. 2012 Jun;26(6):1266-76', 'Pr\u00e9bet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C,', 'Ad\u00e8s L, Quesnel B, Beach CL, Fenaux P, Vey N. Outcome of high-risk myelodysplastic', 'syndrome after azacitidine treatment failure. J Clin Oncol. 2011 Aug 20;29(24):3322-7.', 'Quint\u00e1s-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-', 'Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival', 'compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid', 'leukemia. Blood. 2012 Dec 6;120(24):4840-5.', 'Rauch T. et al, Genome sequencing of pediatric medulloblastoma links catastrophic DNA', 'rearrangements with TP53 mutations. Cell. 2012 Jan 20;148(1-2):59-71.', 'Rubin AI, Chen EH, Ratner D (2005) Current Concepts: Basal-Cell Carcinoma. N Engl J Med; 353:2262-', '9.', 'Rogers HW, Weinstock MA, Harris AR et al (2010) Incidence Estimate of Nonmelanoma Skin Cancer in', 'the United States, 2006. Arch Dermatol; 146:283-7.', 'Rowe JM. Optimal induction and post-remission therapy for AML in first remission. Hematology Am', 'Soc Hematol Educ Program. 2009:396-405.', 'Sargent DJ, Goldberg RM. A flexible design for multiple armed screening trials. Statistics in medicine.', '2001;20(7):1051-1060.', 'Scales SJ, De Sauvage FJ (2009) Mechanisms of Hedgehog pathway activation in cancer and implications', 'for therapy. Trends in Pharmacolgical Sciences;30:303-12.', 'J. H. Schellens, G.S., A. C. Pavlick, R. Tibes, S. Leijen, S. M. Tolaney, I. Diaz-Padilla, R. K.', 'Ramanathan, T. Demuth, J. Viscusi, J. D. Cheng, R. Lam, Y. Xu, A. M. Oza. Update on a phase I', 'pharmacologic and pharmacodynamic study of MK-1775, a Weel tyrosine kinase inhibitor, in', 'monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with', 'advanced solid tumors. J Clin Oncol 29: (suppl; abstr 3068)(2011).']\n\n###\n\n", "completion": "END"}